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Abstract 
Counteraction of drug resistance is a major challenge in cancer therapy, particularly in advanced stages. The main mechanism of 
multidrug resistance is related to an increased rug effiux. In the present study we examined the effect of modifying cell membrane lipid 
fluidity on uptake of adriamycin (ADR) in cells of AKR lymphoma malignancy variants. Modification of cell membrane fluidity, either 
by lecithin or by lecithin-cholesterol mixtures, induced in a high proportion of cells of all variants a higher capacity to accumulate ADR. 
The chemosensitizing effect, for lecithin in particular, was proportional to the degree of malignancy of the lymphoma variants. The 
increased ADR uptake was up to 1.4-fold in the variant of lowest malignancy and up to 5-fold in the one of highest aggressiveness. This 
tendency correlates with our previous studies and is of particular value since highly-malignant tumors are often drug resistant. The 
cholesterol-lecithin mixture, induced, however, in part of the variants the appearance of a small subpopulation with very low ADR 
permeability. Cell membrane rigidification is of value for exposing tumor cell cryptic antigens but may be deleterious when used in 
conjunction with chemotherapy. 
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1. Introduction 
Drug resistance is probably the major mechanism re- 
sponsible for failure of therapy in advanced cancer. One of 
the cell properties which can undergo modifications during 
tumor progression is sensitivity to drugs [1]. The cellular 
alterations occurring during tumor evolution, including the 
emergence of drug resistant clones, impose the necessity to 
test the efficacy of therapeutic means on tumor progression 
models rather than on static ones [2]. 
Tumor cells may lose their sensitivity to several drugs 
simultaneously. The main mechanism responsible for the 
phenomenon of multidrug resistance (MDR) is an in- 
creased drug efflux due to an augmented expression of a 
membrane protein, the P-glycoprotein (Pgp, a 170 kDa 
protein) [3] or the more recently described multidrug resis- 
tance protein, MRP (a 190 kDa protein) [4]. Other non- 
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Pgp-related mechanisms have been described during the 
last years [5-7]. 
Possibilities to counteract drug resistance have been 
explored, particularly with relation to the Pgp-related 
mechanism. Hyperthermia [3,8-10], or membrane active 
agents such as ethanol [11] or tween-80 [12] have been 
shown to reverse drug resistance by augmenting tumor cell 
permeability to drugs. Calcium channel blockers, such as 
verapamil, acting by a different mechanism [13,14], have 
also been found to be effective in counteracting drug 
resistance. 
Cell surface properties may also undergo changes dur- 
ing tumor progression [15,16]. Presuming that the cell 
membrane of highly-malignant tumor cells may be more 
fluid [17], we examined the possibility of affecting cell 
permeability to drugs by membrane active agents, more 
efficiently in high- rather than in low-malignancy cells. It 
is in fact a challenge, to find more efficient therapies 
against he more problematic highly-malignant cells, which 
are often resistant o drugs. Along this strategy, we have 
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found that this was the case in several tumor progression 
models, in both murine [10,12] and human systems [18,19] 
using hyperthermia [10,20], Tween-80 [12] or verapamil 
[21 ] as modulators. 
In the present study we examined the effect of increas- 
ing or decreasing cell membrane fluidity, by modifying its 
content in lecithin or cholesterol, on the retention of 
adriamycin in AKR lymphoma cells derived from variants 
differing in their degree of malignancy. This model of 
T-cell malignancy is of relevance to human T-cell lym- 
phomas which in most cases are resistant to chemotherapy. 
Increasing rigidity of the cell membranes has been used 
in order to enhance immunogenicity of tumor cells by 
exposing cryptic antigens [22]. In the present study our aim 
was the converse, to augment membrane fluidity, in order 
to facilitate permeability to drugs. 
2. Materials and methods 
2.1. AKR lymphoma malignancy variants 
In the present study, four AKR lymphomas differing in 
biological behavior (derived from different spontaneous 
Table I 
Incidence of enlarged inguinal ymph nodes following i.v. inoculation of 
the AKR lymphoma malignancy variants 
Variant Incidence of metastasis 
Day 9 Day 14 
TAU-39 0 /5  1/5 
TAU-33 2 /5  4 /5  
TAU-44 4 /5  5 /5  
TAU-42 5/5  5 /5  
Incidence of experimental metastasis was evaluated in vivo as number of 
mice having tumoral enlarged lymph nodes per total number of animals. 
tumors) were used: TAU-39, of low malignancy, TAU-33 
and TAU-44, of intermediate malignancy and TAU-42 of 
high virulence. The TAU-44 variant has a particular 
predilection for metastasis to certain organs. All four vari- 
ants were originally derived from different spontaneous 
lymphomas. The TAU-39 and TAU-33 have previously 
been isolated and characterized by us [23], while the 
TAU-44 and TAU-42 have been recently isolated [24]. 
The lymphoma variants were maintained by subcuta- 
neous inoculation in the back of AKR/J  mice. The mice 
were obtained and bred at the Animal Breeding Center of 
the Tel-Aviv University. 
Fig. 1. Comparison of dissemination to lungs of the two AKR lymphoma 
variants TAU-39 (a) and TAU-42 (b). Identical inocula (2-105 cells) 
were injected s.c. to AKR/ J  mice. Metastatic spread to lungs and other 
(non-presented) organs was followed by histopathological examination 
after sacrificing mice at the same day after tumor inoculation (day 15). 
Samples were fixed in formalin, embedded in paraffin and stained by H 
and E. Magnification: x 100. Note the dense hyperchromatic area repre- 
senting prominent metastatic growth of the lymphoma seen only in the 
lungs of the TAU-42 variant-bearing mouse (arrow). 
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Fig. 2. Effect of treatment with lecithin or lecithin-cholesterol liposomes 
on ADR uptake of cells derived from the TAU-39 AKR lymphoma 
variant (low malignancy): FACS analysis profiles. 
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Fig. 3. Effect of treatment with lecithin or lecithin-cholesterol liposomes 
on ADR uptake of cells derived from the TAU-33 AKR lymphoma 
variant (intermediate malignancy): FACS analysis profiles. 
big liposomes, amounting to less than 10% of the total 
lipid, were discarded from the sonicated solutions by cen- 
trifugation at 30 000 × g. The obtained liposomes are of a 
small diameter and are suitable for manipulation of mem- 
brane cholesterol [25]. 
2.4. Treatment of  tumor cells with adriamycin and lecithin 
or lecithin-cholesterol Iiposomes 
Lecithin and lecithin-cholesterol were used at 1:50 dilu- 
tion in PBS. Cells of the different AKR lymphoma variants 
(1 • 106/ml) were incubated for 1 h at 37°C as follows: (1) 
without treatment; (2) with ADR (8.6-86 /xM) alone; (3) 
with lecithin liposomes (LE) alone; (4) with lecithin- 
cholesterol liposomes (LE-CHOL) alone; (5) with ADR + 
LE; (6) with ADR + LE-CHOL. 
2.5. Fluorescence Associated Cell Sorter (FACS) analysis 
Based on the fluorescence of ADR, cytofluorimetric 
analysis of the AKR lymphoma-treated cells was per- 
formed in a FACS IV Beckton-Dickinson (Mountain View, 
CA, USA) combined with Consort 40 data processing. 
ADR fluorescence was detected through an LP 570 filter. 
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For the experiments, single cell suspensions were pre- 
pared as previously described [2]. In short, tumors were 
excised and placed in RPMI medium. After mincing, the 
cell suspension was filtered through several layers of 
gauze to discard cell aggregates. 
2.2. Adriamycin 
Adriamycin (ADR) was purchased from Farmitalia, Italy 
and dissolved in double distilled water before use. 
2.3. Liposome preparation 
Liposomes of lecithin or of lecithin-cholesterol (1:1, 
mol /mol)  were prepared as follows. Solutions of 80 mg of 
egg lecithin or 80 mg of egg lecithin mixed with 40 mg 
cholesterol in chloroform-methanol (2:1, v /v )  were evapo- 
rated to dryness under nitrogen and dispersed in 5 ml PBS. 
The dispersions were then subjected to an ultrasonic irradi- 
ation with a Braun-Sonic 300 sonicator (B. Braun, Melsun- 
gen, Germany). Sonication was carried out with ice cool- 
ing using a 9-mm diameter tip at maximum energy output 
for 10 min for liposomes of lecithin, and for 40 min for 
liposomes of lecithin-cholesterol. Insoluble material and 
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Fig. 4. Effect of treatment with lecithin or lecithin-cholesterol liposomes 
on ADR uptake of cells derived from the TAU-44 AKR lymphoma 
variant (intermediate malignancy): FACS analysis profiles. 
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3. Results 
3.1. Comparison of the malignant behavior of the AKR 
lymphoma variants 
A comparison between the rate of tumor growth of the 
four AKR lymphoma variants, as assessed in vivo by the 
cumulative incidence of tumoral enlarged inguinal lymph 
nodes, is presented in Table 1. The observed order of 
metastatic apacity was TAU42 > TAU-44 > TAU-33 > 
TAU-39. Fig. 1 compares the microscopic dissemination to
lungs of the two extreme variants, TAU-39, of low- 
malignancy (LM) and TAU-42 of high-malignancy (HM). 
While practically no lung metastases were seen in the LM 
variant, HM displayed massive invasion of the organ. 
3.2. Effect of lecithin and lecithin-cholesterol liposomes on 
intracellular accumulation of ADR in the AKR lymphoma 
uariants 
Adriamycin retention in cells derived from the four 
AKR lymphoma variants in single treatment or in combi- 
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Fig. 5. Effect of treatment with lecithin or lecithin-cholesterol liposomes 
on ADR uptake of cells derived from the TAU-42 AKR lymphoma 
variant (high malignancy): FACS analysis profiles. 
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Fig. 6. Increase in the high retention population (HRP) induced by the 
membrane fluidity modifiers in the four AKR lymphoma variants. In- 
crease in HRP = HRP of cells treated with ADR + Lec or Lec-Chol/HRP 
of cells treated with ADR alone. The data are those presented in the last 
column of Table 2. 
nation with lecithin or lecithin-cholesterol mixture is pre- 
sented in Figs. 2-5, for the TAU-39, TAU-33, TAU-44 
and TAU-42, respectively. Quantitative valuations of these 
FACS data are given in Table 2 and Fig. 6. 
Very marked differences among the lymphoma variants 
were recorded with regard to the chemosensitizing effect 
of lecithin or lecithin-cholesterol. 
The cells derived from the variant of the lowest malig- 
nancy, TAU-39, were not affected by the membrane active 
agents when used in conjunction with ADR at 17.3 /xM/1 
• 10  6 cells/ml. At the higher ADR concentration, slight 
increases in ADR uptake were observed, particularly with 
lecithin treatment. Very pronounced shifts of cell popula- 
tions towards higher peaks were observed with all the 
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Fig. 7. Effect of adriamycin (86.5 /xM) as single treatment or in 
combination with lecithin on viability of the TAU-42 AKR lymphoma 
variant. 
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Table 2 
Effect of lecithin and lecithin-cholesterol on adriamycin retention i cells of AKR lymphoma malignancy variants - FACS analysis according tocontent in
cellular subpopulations 
Variant ADR Chemosensitizer Subpopulations (%) Ratio of HRP 
concentration VLRP LRP IRP HRP with Le or Le/Ch 
(tzM) per control HRP 
TAU-39 17.3 - 64 36 
17.3 Le 75 25 0.69 
17.3 Le/Ch 73 27 0.75 
51.9 - 81 19 
51.9 Le 73 27 1.42 
51.9 Le/Ch 76 24 1.26 
TAU-33 17.3 - 39 44 17 
17.3 Le 29 29 42 2.47 
17.3 Le/Ch 5 46 49 2.88 
86.5 - 37 50 13 
86.5 Le 22 39 39 3.00 
86.5 Le/Ch 5 36 59 4.54 
TAU-44 17.3 - 41 42 17 
17.3 Le 19 19 62 3.65 
17.3 Le/Ch 45 14 41 2.41 
86.5 - 48 37 15 
86.5 Le 18 18 64 4.27 
86.5 Le/Ch 42 13 45 3.00 
TAU-42 8.65 - 83 17 
8.65 Le 25 14 86 5.06 
8.65 Le/Ch 13 62 3.65 
86.5 - 74 26 
86.5 Le 12 88 3.38 
86.5 Le/Ch 10 16 74 2.85 
VLRP, Very low retention population; LRP, low retention population; IRP, intermediate retention population; HRP, high retention population. I crease in
HRP = HRP of cells treated with ADR + Lec or Lec-Chol/HRP of cells treated with ADR alone. 
other more malignant variants, TAU-33, TAU-44 and 
TAU-42. Moreover, there was a tendency of increase of 
the chemosensitizing effect of both agents, proportional to 
the malignancy of the variant. Generally, the effect of 
lecithin alone was greater than that of the lecithin- 
cholesterol mixture (see Fig. 6). Interestingly, small peaks 
of very low retention populations (VLRP) appeared in the 
presence of cholesterol-lecithin. This was particularly evi- 
dent in the TAU-44 and TAU-42 variants. These VLRP 
cells were not observed among the cells treated with ADR 
alone. 
As for lecithin, at the low ADR concentration, there 
was no increase in the high retention population (HRP) in 
the low-malignancy variant, TAU-39 (see Table 2). How- 
ever, a 2-3-fold increase in the two variants of intermedi- 
ate-malignancy, TAU-33 and TAU-44, and a 5-fold in- 
crease in the variant of highest malignancy, TAU-42, were 
observed. A similar trend of a more efficient chemosensi- 
tizing effect in the highly malignant variants was also 
induced by the lecithin-cholesterol treatment, although to a 
lower extent. At the high ADR concentration, slight aug- 
mentations in HRP was seen in the low-malignancy vari- 
ant, with the two membrane modifiers. High increases in 
HRP (3-4-fold) were observed in the other three variants 
upon treatment with either lecithin or lecithin-cholesterol. 
At the high ADR concentration, the correlation between 
the degree of malignancy and efficacy of chemosensitizing 
effect of the two membrane modifiers was less evident. 
The effect of ADR as single treatment or in combina- 
tion with lecithin on cell viability, as assessed by Trypan 
blue exclusion is shown in Fig. 7. While ADR alone did 
not affect cell viability in the conditions used, the com- 
bined ADR-lecithin treatment reduced viability of the tu- 
mor cells by 64%. 
4. D iscuss ion  
During the process of tumor progression, modifications 
in morphology [26], karyotype [27], cell surface structure 
[28,29], antigenicity [30] and sensitivity to drugs [31,32] 
take place. The latter is often reflected in multidrug resis- 
tance (MDR), which is a serious problem in clinical oncol- 
ogy. Membrane active agents may increase cell permeabil- 
ity to drugs, thereby counteracting the MDR phenotype. 
Since cell membranes of highly-malignant (HM) cells have 
been found to be more fluid than those of low-malignancy 
(LM) ones [17], we have suggested that HM cells might be 
more susceptible than LM cells to the chemosensitizing 
effect of membrane active agents [20]. We have indeed 
found that this was the case in most [10,12,18-21] al- 
though not all [20] models used by us. It should be noted 
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that the partitioning of anthracycline aminoglycosides, the 
compound family of ADR, into cell membranes i deter- 
mined by the membrane lipid fluidity [33]. Therefore, the 
latter has been assumed to be a critical factor in the 
potency of anthracycline drugs [33]. 
In the present study we have found that by modifying 
the fluidity of the cell membrane, either by lecithin or 
treatment with liposomes of lecithin-cholesterol mixture, a 
high proportion of the treated lymphoma cells acquire a 
higher capacity of accumulating ADR. This increase in 
ADR uptake was low in the low-malignancy variants and 
considerably higher in the highly-malignant ones. On the 
whole, the susceptibility to chemosensitizing by lecithin 
and to a lesser extent by lecithin-cholesterol, was directly 
proportional to the degree of malignancy of the AKR 
lymphoma variants. This was particularly evident with 
lecithin at the low concentration of ADR used here (see 
Fig. 4). This tendency is in accordance with our previous 
findings with various membrane active agents in different 
tumor progression models [10,12,18-21]. Our results 
therefore indicate that the effect of our treatments are 
multi-functional and probably involved simultaneous 
changes in lipid fluidity and in protein exposure. 
The high augmentation i adriamycin intracellular re- 
tention induced by lecithin could be due to the high 
affinity binding of the drug to DNA. The bound ADR then 
does not contribute any more to the equilibrium between 
influx and effiux of the drug. This drives the balance 
towards a higher influx of the cytotoxic agent. In addition, 
if adriamycin attaches to a membrane receptor, not only 
diffusion will act, and higher influx than effiux is ex- 
pected. 
One of the tools previously used by us as a chemosensi- 
tizer is hyperthermia. It has been found by other laborato- 
ries [8,9] and by us [10,19,20] that hyperthermia can 
counteract drug resistance via an increase of cell perme- 
ability to the drug. Moreover, the effect of hyperthermia 
was more pronounced on high- than on low-malignancy 
cells. One of the main targets of supranormal temperatures 
is the cell membrane. Hyperthermia ncreases cell mem- 
brane fluidity [34] and its effect depends on the lipid 
content, in particular the cholesterol level [35-37]. 
Structural cell membrane changes induced by modifica- 
tion in cell fluidity may cause functional alterations due to 
changes in protein position, like exposure of antigens by 
vertical displacement or growth factor receptors or lateral 
mobility of receptors [38,39]. These have indeed been 
found to occur both following cell treatment by hyperther- 
mia [34,40,41] and by modifying the cholesterol content of 
cells [39,42]. In this context, it is possible to presume that 
modifying the cholesterol content of the cell membrane 
could lead, in addition to modification in membrane fluid- 
ity, which is in itself relevant o drug resistance, to an 
alteration in exposure or function of the Pgp, modifying 
thereby drug resistance. 
Marked decrease in membrane phospholipids accompa- 
nies irreversible ischemic injury, demonstrating their im- 
portance in the membrane structure. Lecithin (phospha- 
tidylcholine) is the major membrane phospholipid in all 
eukaryotes. In virtually all cell membranes, its level ex- 
ceeds by far the other phospholipids. 
Cholesterol content of the cell membrane can determine 
the molecular structure of the lipid bilayer. Cholesterol is 
nonrandomly organized in the plasma membrane. The 
asymmetry of the cell membrane is manifested in an 
uneven transbilayer cholesterol distribution, the inner 
leafet being more rich in cholesterol than the outer one 
[43]. In the lateral plane of the cell membrane, rich and 
poor cholesterol domains were described [44]. These 
cholesterol domains are of importance for the location, 
structure and function of transmembrane proteins. Some 
proteins are located in rich [45], others in poor [46] choles- 
terol domains. Cholesterol appears to be required for the 
function of membranal enzymes [47], transport proteins 
[48], ion channels [49] or receptors [50], part of which may 
be of importance in both tumor progression and resistance 
to drugs. 
Interaction of drugs with the membrane lipid bilayer 
may also be affected by the content in cholesterol. Plasma 
membrane lipid composition may influence binding and 
partitioning of the drugs in the cell membrane and thereby 
their bioavailability and pharmacological activity [51]. 
The cell membrane represents with regard to adri- 
amycin, not only a physical barrier: it can serve by itself a 
target for its cytotoxic activity [52]. Acquisition of drug 
resistance may therefore be caused by cell membrane 
alterations of different ypes [53]. Resistance to ADR can 
be acquired following modifications in membrane choles- 
terol via alteration of membrane fluidity [54], changing 
thereby diffusion of the lipophilic ADR through the lipid 
bilayer [53]. Resistance to ADR has indeed been found to 
be related to increased cholesterol content of the cell 
membrane [55-57], although reduced sterol content has 
also been reported [53]. 
While the effect of lecithin treatment could be related to 
membrane fluidization, the analogous effect with lecithin- 
cholesterol liposomes seems to be a net of a series of 
simultaneous changes. 
The cholesterol-lecithin mixture caused an increase in 
cell permeability to ADR, although to a lesser extent han 
lecithin. However, in part of the variants, a small subpopu- 
lation of cells became less permeable to the chemothera- 
peutic agent. The rigidification of the cell membrane upon 
incorporation of cholesterol might bear a value for the 
exposure of cryptic sites [38]. It could, however, induce 
deleterious consequences in combination with chemo- 
therapy. In this respect, treatment with lecithin is expected 
to be the most beneficial. 
The levels of ADR exceed those applied in the clinics. 
Adjustment o a pharmacological therapeutic range evi- 
dently still necessitates a quantitative valuation of the 
efficiency and toxicity of the drugs in an in vivo system. 
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Yet this in vitro stimulation can still possibly contribute to 
a new approach in the counteraction of drug resistance, 
particularly in the late stages of tumor progression, when 
this problem is critical. 
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